Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer, began construction of a state-of-the-art facility in Spokane, WA.

The company specializes in the manufacture (fill and finish) of injectable drugs, including vaccines and biologics. The new facility will add critically needed capacity for the manufacture of commercial and clinical trial drugs.

The 145,000 sq.-ft. facility is designed for contract manufacturing of injectable pharmaceuticals and will incorporate industry-leading technology, including isolator-based filling systems and electronic batch records. The initial investment is approximately $90 million, and the facility is scheduled to be commissioned by 2Q22.
 
Selkirk has 25 employees and plans to increase staffing to 45 by mid-2022. At full capacity, the facility will employ 300 scientists, engineers, and operations personnel.
 
Selkirk and its partners plan to invest an additional $60 million in the facility over the next three to five years as production lines and capabilities are added. Selkirk also plans to build a second manufacturing facility on an adjacent 8-acre parcel at a later date.

Read Contract Pharma’s Exclusive Interview with Patrick Haffey, Selkirk’s Chief Executive Officer.